Comment on: a multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation.

Hepatobiliary Surg Nutr

Department of HPB and Liver Transplantation, Beaujon Hospital, University of Paris, APHP, Clichy, France.

Published: April 2022

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023839PMC
http://dx.doi.org/10.21037/hbsn-22-84DOI Listing

Publication Analysis

Top Keywords

comment multicentre
4
multicentre outcome
4
outcome analysis
4
analysis define
4
define global
4
global benchmarks
4
benchmarks donation
4
donation circulatory
4
circulatory death
4
death liver
4

Similar Publications

We would like to express our sincere gratitude for the thoughtful reflections on our recent study regarding pulmonary metastasectomy, and we greatly appreciate the constructive dialog that our work has sparked [...

View Article and Find Full Text PDF

Regional action needed to halt antimalarial drug resistance in Africa.

Lancet

December 2024

Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok 10400, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; WorldWide Antimalarial Resistance Network, Oxford, UK. Electronic address:

View Article and Find Full Text PDF

Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy.

World J Hepatol

November 2024

Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Rome 00185, Italy.

Hepatic encephalopathy (HE) is one of the main complications of cirrhosis, characterized by a wide spectrum of neuropsychiatric alterations that lead to an increase in mortality, morbidity and recurrent hospitalizations. Due to the central role in HE pathogenesis of ammonia and other neurotoxins primarily produced by the gut microbiota, the main therapeutic approaches for the treatment of HE are based on the modulation of the gut microbiota. Rifaximin is a non-absorbable broad-spectrum antibiotic, that is effective against ammonia-producing gram-positive, gram-negative, and anaerobic species, approved for the treatment of HE in secondary prophylaxis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!